Full Press Release Details
CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in panel discussion and host one-on-one investor meetings at the 4thAnnual Roth Healthcare Opportunities Conference, being held on October 9, 2025, in New York, NY.
Roth Healthcare Opportunities ConferenceFormat: Panel discussion and one-on-one meetingsPanel Title: “Small Firms Tackling Blockbuster Indications”Date: Thursday, October 9, 2025Time: 8:00 AM ET
To learn more and submit a registration request, clickhere. Reviva’s management team will be available for one-on-one investor meetings on October 9, 2025.
About RevivaReviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.